A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine Plus LY293111 Compared to Gemcitabine Plus Placebo in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00055250

Enrollment

130

Registered

2003-02-24

Start date

2003-01-31

Completion date

2005-10-31

Last updated

2007-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Brief summary

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.

Interventions

DRUGGemcitabine

DRUGLY293111

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent * Tumor that can be measured by x-ray or scan * Adequate organ function

Exclusion criteria

* Inability to swallow capsules * Documented brain metastases * Prior chemotherapy or biological therapy for this disease

Design outcomes

Primary

Measure	Time frame
6-month survival	—

Secondary

Measure	Time frame
Toxicity	—
tumor response	—
PK	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026